scholarly journals Associations between continuous glucose monitoring-derived metrics and diabetic retinopathy and albuminuria in patients with type 2 diabetes

2021 ◽  
Vol 9 (1) ◽  
pp. e001923
Author(s):  
Satomi Wakasugi ◽  
Tomoya Mita ◽  
Naoto Katakami ◽  
Yosuke Okada ◽  
Hidenori Yoshii ◽  
...  

IntroductionPreventing the development and progression of diabetic microvascular complications through optimal blood glucose control remains an important challenge. Whether metrics based on continuous glucose monitoring are useful for the management of diabetic microvascular complications is not entirely clear.Research design and methodsThis is an exploratory analysis of an ongoing prospective, multicenter, 5-year follow-up observational study. Study participants included 999 outpatients with type 2 diabetes who underwent continuous glucose monitoring at baseline. Associations between continuous glucose monitoring-derived metrics and the severity of diabetic retinopathy or albuminuria were investigated using multivariable proportional odds models.ResultsThe overall prevalence of diabetic retinopathy was 22.2%. Multivariate analysis with proportional odds models demonstrated that continuous glucose monitoring-derived metrics related to intraday and interday glucose variability are significantly associated with the severity of diabetic retinopathy, even after adjusting for various possible risk factors. However, significant relationships were not observed after adjusting for hemoglobin A1c (HbA1c) levels. The prevalence of microalbuminuria and macroalbuminuria was 20.3% and 6.7%, respectively. Similarly, multivariate analysis demonstrated that those metrics are significantly associated with the severity of albuminuria. These relationships remained significant even after further adjusting for HbA1c levels.ConclusionsContinuous glucose monitoring-derived metrics related to intraday and interday glucose variability are significantly associated with the severity of diabetic retinopathy or albuminuria in patients with type 2 diabetes. Thus, evaluating these metrics might possibly be useful for risk assessment of diabetic microvascular complications.Trial registration number UMIN000032325.

2020 ◽  
Author(s):  
Satomi Wakasugi ◽  
Tomoya Mita ◽  
Naoto Katakami ◽  
Yosuke Okada ◽  
Hidenori Yoshii ◽  
...  

Abstract BackgroundPreventing the development and progression of diabetic microvascular complications through optimal blood glucose control remains an important challenge. Whether metrics based on continuous glucose monitoring are useful for the management of diabetic microvascular complications is not entirely clear.MethodsThis is an exploratory analysis of an ongoing prospective, multicenter, 5-year follow-up observational study. Study participants included 999 outpatients with type 2 diabetes who underwent continuous glucose monitoring at baseline. Associations between continuous glucose monitoring-derived metrics and the severity of diabetic retinopathy or albuminuria were investigated using multivariable proportional odds models.ResultsThe overall prevalence of diabetic retinopathy was 22.2%. Multivariate analysis with proportional odds models demonstrated that continuous glucose monitoring-derived metrics related to intra-day and inter-day glucose variability are significantly associated with the severity of diabetic retinopathy, even after adjusting for various possible risk factors. However, significant relationships were not observed after adjusting for HbA1c levels. The prevalence of microalbuminuria and macroalbuminuria were 20.3% and 6.7%, respectively. Similarly, multivariate analysis demonstrated that those metrics are significantly associated with the severity of albuminuria. These relationships remained significant even after further adjusting for HbA1c levels. ConclusionsContinuous glucose monitoring-derived metrics related to intra-day and inter-day glucose variability are significantly associated with the severity of diabetic retinopathy or albuminuria in patients with type 2 diabetes. Thus, evaluating these metrics might possibly be useful for risk assessment of diabetic microvascular complications.


2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Dulce Adelaida Rivera-Ávila ◽  
Alejandro Iván Esquivel-Lu ◽  
Carlos Rafael Salazar-Lozano ◽  
Kyla Jones ◽  
Svetlana V. Doubova

Abstract Background The study objective was to evaluate the effects of professional continuous glucose monitoring (CGM) as an adjuvant educational tool for improving glycemic control in patients with type 2 diabetes (T2D). Methods We conducted a three-month quasi-experimental study with an intervention (IGr) and control group (CGr) and ex-ante and ex-post evaluations in one family medicine clinic in Mexico City. Participants were T2D patients with HbA1c > 8% attending a comprehensive diabetes care program. In addition to the program, the IGr wore a professional CGM sensor (iPro™2) during the first 7 days of the study. Following this period, IGr participants had a medical consultation for the CGM results and treatment adjustments. Additionally, they received an educational session and personalized diet plan from a dietitian. After 3 months, the IGr again wore the CGM sensor for 1 week. The primary outcome variable was HbA1c level measured at baseline and 3 months after the CGM intervention. We analyzed the effect of the intervention on HbA1c levels by estimating the differences-in-differences treatment effect (Diff-in-Diff). Additionally, baseline and three-month CGM and dietary information were recorded for the IGr and analyzed using the Student’s paired t-test and mixed-effects generalized linear models to control for patients’ baseline characteristics. Results Overall, 302 T2D patients participated in the study (IGr, n = 150; control, n = 152). At the end of the three-month follow-up, we observed 0.439 mean HbA1C difference between groups (p = 0.004), with an additional decrease in HbA1c levels in the IGr compared with the CGr (Diff-in-Diff HbA1c mean of − 0.481% points, p = 0.023). Moreover, compared with the baseline, the three-month CGM patterns showed a significant increase in the percentage of time in glucose range (+ 7.25; p = 0.011); a reduction in the percentage of time above 180 mg/dl (− 6.01; p = 0.045), a decrease in glycemic variability (− 3.94, p = 0.034); and improvements in dietary patterns, shown by a reduction in total caloric intake (− 197.66 Kcal/day; p = 0.0001). Conclusion Professional CGM contributes to reducing HbA1c levels and is an adjuvant educational tool that can improve glycemic control in patients with T2D. Trial registration ClinicalTrials.gov: NCT04667728. Registered 16/12/2020


2020 ◽  
Author(s):  
Xinyu Wang ◽  
Litong Yao ◽  
Xiang Li ◽  
Yifan Zhong ◽  
Yan Wang ◽  
...  

Abstract Background: Current evidences supported a highly relevant between acid-load and diabetes. The rise of serum anion gap (AG) has performed the significances in metabolic acidosis. Some factors correlated to diabetes might affect its complications such as diabetic retinopathy (DR).Methods: A total of 3,411 Chinese adults with type 2 diabetes were selected form the hospital registry data on DR Sub-study of Liaoning Diabetic Microvascular Complications Study (LD-MCS), included 1,137 DR as the cases and 2,274 non-DR as the matching controls. Fasting venous blood test was applied to ascertain the ion levels, and serum AG (mmol/L) was computed by: AG = (sodium + potassium) – (chlorine + bicarbonate). According to Early Treatment for Diabetic Retinopathy Study standards, DR was diagnosed by two-field fundus photographs and classified as mild non-proliferative DR (NPDR), moderate NPDR, and vision-threatening DR (VTDR). Logistic regression models and linear regression models were used to analyze the relationships.Results: In setting of the non-acidosis, higher AG was significantly associated with DR (P = 0.001), increased with aggravating retinopathy but decreased in VTDR level (P < 0.001). Multivariable-adjusted models showed that AG quartiles were independently linked with higher odds to occurrence (P for trend < 0.001) and severity (P for trend < 0.05) of DR, but with attention to the fluctuation of 75th AG quartiles. Linear logistic regression by stepwise method suggested the growth of age (P = 0.014), glycated hemoglobin (P = 0.018), and the homeostasis model assessment of insulin resistance index (P < 0.001) played an intimate role in the association between AG and DR.Conclusions: Higher AG was independently related to the occurrence and progression of DR. Our findings suggested that serum AG might alter the risk of DR by affecting glucose metabolism and insulin sensitivity in patients with type 2 diabetes.


2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Lina H. M. Ahmed ◽  
Alexandra E. Butler ◽  
Soha R. Dargham ◽  
Aishah Latif ◽  
Amal Robay ◽  
...  

Abstract Aims Vitamin D measurement is a composite of vitamin D2 (25(OH)D2) and D3 (25(OH)D3) levels, and its deficiency is associated with the development of type 2 diabetes (T2DM) and diabetic complications; vitamin D deficiency may be treated with vitamin D2 supplements. This study was undertaken to determine if vitamin D2 and D3 levels differed between those with and without T2DM in this Middle Eastern population, and the relationship between diabetic microvascular complications and vitamin D2 and vitamin D3 levels in subjects with T2DM. Methods Four hundred ninety-six Qatari subjects, 274 with and 222 without T2DM participated in the study. Plasma levels of total vitamin D2 and D3 were measured by LC-MS/MS analysis. Results All subjects were taking vitamin D2 and none were taking D3 supplements. Vitamin D2 levels were higher in diabetics, particularly in females, and higher levels were associated with hypertension and dyslipidemia in the diabetic subjects (p < 0.001), but were not related to diabetic retinopathy or nephropathy. Vitamin D3 levels measured in the same subjects were lower in diabetics, particularly in females (p < 0.001), were unrelated to dyslipidemia or hypertension, but were associated with retinopathy (p < 0.014). Neither vitamin D2 nor vitamin D3 were associated with neuropathy. For those subjects with hypertension, dyslipidemia, retinopathy or neuropathy, comparison of highest with lowest tertiles for vitamin D2 and vitamin D3 showed no difference. Conclusions In this Qatari cohort, vitamin D2 was associated with hypertension and dyslipidemia, whilst vitamin D3 levels were associated with diabetic retinopathy. Vitamin D2 levels were higher, whilst vitamin D3 were lower in diabetics and females, likely due to ingestion of vitamin D2 supplements.


Nephron ◽  
2020 ◽  
Vol 145 (1) ◽  
pp. 27-34
Author(s):  
Tobias Bomholt ◽  
Thomas Idorn ◽  
Filip K. Knop ◽  
Morten B. Jørgensen ◽  
Ajenthen G. Ranjan ◽  
...  

<b><i>Aims:</i></b> The aim of this study was to evaluate the effect of liraglutide treatment on glucose variability and the risk of hypoglycemia by continuous glucose monitoring (CGM) in persons with type 2 diabetes (T2D) and dialysis-dependent end-stage renal disease (ESRD). <b><i>Materials and Methods:</i></b> We assessed CGM data from a previous trial where 24 persons with T2D and dialysis-dependent ESRD were allocated (1:1) to 12 weeks of double-blinded treatment with liraglutide (titrated to maximum tolerable dose up to 1.8 mg) or placebo as an add-on to preexisting antidiabetic treatment. CGM (Ipro2<sup>®</sup>; Medtronic) was performed for up to 7 days at baseline and at weeks 2, 6, and 10. A linear mixed model was used to compare the 2 study arms. <b><i>Results:</i></b> A CGM was worn at baseline by 12 persons in the liraglutide group and 10 in the placebo group (7 and 9 completed week 10, respectively). Glycated hemoglobin A<sub>1c</sub> (<i>p</i> = 0.81) and glucose variability was similar between the groups (standard deviation, <i>p</i> = 0.33; coefficient of variation, <i>p</i> = 0.16). Comparing baseline and week 10, the number of hypoglycemic events (glucose values between &#x3c;3.9 and 3.0 mmol/L) increased in the liraglutide group compared with the placebo group (<i>p</i> = 0.02). The occurrence of hypoglycemic events below 3.0 mmol/L was similar between the groups (<i>p</i> = 0.36). <b><i>Conclusions:</i></b> In the present cohort of persons with T2D and dialysis-dependent ESRD, liraglutide treatment increased the risk of hypoglycemic events as compared to placebo (no difference was found for hypoglycemic events below 3.0 mmol/L). The majority of participants were co-treated with insulin.


Sign in / Sign up

Export Citation Format

Share Document